The combined action of TGF-β1 and IL-18 on NKp30 expression may significantly impair the NK-mediated tumor immune surveillance as well as the “DC editing” process, allowing the survival of MHC class Ilow DCs that, due to the inappropriate antigen presentation, could promote tolerogenic responses. The gene discussed is TGFB1; the disease is neoplasm.